METiS TechBio

Research on the record

• 2025-12-15METiS designed its liver-cancer drug's mRNA sequence with its own algorithm, and the drug cleared tumours in miceLevel 4 · Tested in the physical world
• 2025-10-23METiS says MTS-004, a tablet whose formulation its own AI tool designed, met the primary endpoint of a 264-patient Phase 3 in uncontrollable laughing and cryingLevel 5 · Used in practice

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-19METiS TechBio will design lipids for Eli Lilly with its own AI platform, under a collaboration worth up to about $1.1B in milestonesPartnerships
• 2026-05-13METiS, which designs drug formulations with AI, lists in Hong KongCapital

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-05-13IPO · about HK$2.113B grossconfirmedAnchored by BlackRock, UBS AM Singapore, China Venture Capital Innovation Investment Fund, Mirae Asset, HHLRA (Hillhouse), Deerfield, RTW, Arc Avenue, Huadeng Technology, Isometry Global, GF Fund Management, ICBC UBS Asset Management, ChinaAMC (Hong Kong), Fullgoal Fund Management, Lake Bleu, Sage Partners, ICBC Wealth Management, ORIX Asia AMStated use: AI nanomaterial platform (~50%), clinical trials (~20%), animal health and anti-ageing (~10%), global ecosystem (~10%)
• 2025-08-04Series D · CNY 400MconfirmedLed by Beijing Pharma & Health Industry Investment Fund, Daxing District Industry Investment FundStated use: platform automation, pipeline, international deals, hiring
• 2024-06-21Series C · $100MconfirmedLed by CICC Capital fund · With Taiping Hong Kong insurance tech fundStated use: AI delivery platform and in-house pipeline
• 2022-04-06Round (unnamed) · $150MconfirmedLed by PICC Capital, China Life Equity · With Sequoia China, 5Y Capital, CMB International, Lightspeed China, Monolith, FreeS FundStated use: AI drug and delivery platform; small-molecule and nucleic-acid pipeline
• 2020-12-03Angel+ · over 100 million yuanconfirmedLed by Sequoia China · With FreeS Fund, Source Code Capital, XtalPi, Forcefield VentureStated use: more pharma partnerships, take its formulation pipeline into clinical trials, extend AI formulation to intracellular delivery and large molecules
• 2020-12-03Pre-A · over 100 million yuanconfirmedLed by Lightspeed China Partners · With 5Y CapitalStated use: more pharma partnerships, take its formulation pipeline into clinical trials, extend AI formulation to intracellular delivery and large molecules
• 2020-03-23Angel · several million US dollarsconfirmedLed by FreeS Fund · With Source Code Capital, XtalPi (strategic)Stated use: AI formulation platforms in China and the US; formulation pipeline

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →